| Literature DB >> 32373060 |
Jordi A Matias-Guiu1, Ana Cortés-Martínez1, Rosie E Curiel2, Alfonso Delgado-Álvarez1, Aníbal Fernández-Oliveira3, Vanesa Pytel1, Paloma Montero1, Teresa Moreno-Ramos1, David A Loewenstein2, Jorge Matías-Guiu1.
Abstract
Objective: Episodic memory is frequently impaired in Multiple Sclerosis (MS), but the cognitive characteristics and neuropsychological processes involved remain controversial. Our aim was to study episodic memory dysfunction in MS, using the LASSI-L, a novel memory-based cognitive stress test that uses a new paradigm that capitalizes on semantic interference.Entities:
Keywords: memory; multiple sclerosis; neuropsychological assessment; proactive interference; semantic
Year: 2020 PMID: 32373060 PMCID: PMC7186484 DOI: 10.3389/fneur.2020.00309
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Summary of LASSI-L scores.
| FRA1 | Free Recall List A Trial 1 | Encoding |
| CRA1 | Cued Recall List A Trial 1 | Initial learning |
| CRA2 | Cued Recall List B Trial 2 | Maximum storage |
| FRB1 | Free Recall List B Trial 1 | Proactive semantic interference (free recall) |
| CRB1 | Cued Recall List B Trial 1 | Proactive semantic interference (cued recall) |
| CRB2 | Cued Recall List B Trial 2 | Recovery from proactive semantic interference |
| SdFRA | Short Delay Free Recall List A | Retroactive interference (free recall) |
| SdCRA | Short Delay Cued Recall List A | Retroactive interference (cued recall) |
| DR | Delayed Recall | Free Delayed Recall |
Correlations between LASSI-L scores and FCSRT, FSS, BDI, and EDSS.
| FCSRT 1-minute free recall | 0.265 | 0.265 | 0.364 | 0.295 | 0.295 | 0.346 | 0.354 | 0.347 | 0.465 |
| FCSRT total free recall | 0.347 | 0.363 | 0.503 | 0.401 | 0.343 | 0.462 | 0.479 | 0.449 | 0.581 |
| FCSRT total recall | 0.255 | 0.374 | 0.527 | 0.354 | 0.304 | 0.506 | 0.422 | 0.430 | 0.570 |
| FCSRT delayed free recall | 0.361 | 0.360 | 0.466 | 0.384 | 0.342 | 0.505 | 0.498 | 0.465 | 0.564 |
| FCSRT delayed total recall | 0.346 | 0.400 | 0.597 | 0.407 | 0.303 | 0.541 | 0.388 | 0.354 | 0.524 |
| FSS | −0.265 | −0.228 | −0.179 | −0.294 | −0.244 | −0.201 | −0.191 | −0.206 | −0.283 |
| BDI | −0.289 | −0.219 | −0.226 | −0.219 | −0.192 | −0.284 | −0.126 | −0.165 | −0.267 |
| EDSS | −0.029 | 0.005 | −0.103 | −0.007 | −0.138 | 0.003 | −0.061 | −0.049 | 0.012 |
FCSRT, Free and Cued Selective Reminding Test; FSS, Fatigue Severity Scale; BDI, Beck Depression Inventory; EDSS, Expanded Disability Status Scale.
p < 0.05.
p < 0.01.
Figure 1Frequency of scores in MS patients (green) and HC (blue) in the LASSI-L scores [(A) FRA1; (B) FRB1; (C) SdFRA; (D) DR] and in the Free and Cued Selective Reminding Test [(E) total delayed recall].
Mean comparison between MS vs. HC on LASSI-L scores.
| FRA1 | HC | 10.60 ± 2.37 | 3.684 | 0.50 | |
| MS | 9.39 ± 2.41 | ||||
| CRA1 | HC | 11.07 ± 1.96 | 4.485 | 0.62 | |
| MS | 9.73 ± 2.32 | ||||
| CRA2 | HC | 13.46 ± 1.48 | 1.950 | 0.053 | 0.26 |
| MS | 13.01 ± 1.90 | ||||
| FRB1 | HC | 8.17 ± 2.39 | 3.505 | 0.48 | |
| MS | 7.03 ± 2.31 | ||||
| CRB1 | HC | 8.89 ± 5.08 | 3.392 | 0.41 | |
| MS | 7.22 ± 2.51 | ||||
| CRB2 | HC | 12.27 ± 1.91 | 3.781 | 0.51 | |
| MS | 11.19 ± 2.29 | ||||
| SdFRA | HC | 8.46 ± 2.87 | 5.465 | 0.75 | |
| MS | 6.32 ± 2.81 | ||||
| SdCRA | HC | 9.67 ± 2.65 | 4.534 | 0.62 | |
| MS | 8.02 ± 2.65 | ||||
| DR | HC | 22.02 ± 3.64 | 4.474 | 0.60 | |
| MS | 19.47 ± 4.72 | ||||
Statistically significant p-values are shown in bold.
Figure 2Plot of intersections between LASSI-L subscales (z-scores <-1.0) in MS patients. The bar chart on the left indicates the total number of patients showing LASSI-L score below the cutoff. The upper bar chart shows the number of cases displaying the intersection. Dark connected dots on the bottom panel indicate which subscales are considered for each intersection.
LASSI-L performance (scores) across diagnostic groups.
| FRA1 | 10.60 ± 2.37 | 9.63 ± 2.31 | 9.07 ± 2.52 | 7.42 | 0.065 | |
| CRA1 | 11.07 ± 1.96 | 10.27 ± 2.23 | 9.05 ± 2.29 | 14.76 | 0.121 | |
| CRA2 | 13.46 ± 1.48 | 13.81 ± 1.22 | 12.00 ± 2.13 | 17.25 | 0.139 | |
| FRB1 | 8.17 ± 2.39 | 7.50 ± 1.97 | 6.44 ± 2.59 | 8.59 | 0.074 | |
| CRB1 | 8.48 ± 2.87 | 7.31 ± 2.49 | 7.10 ± 2.57 | 5.79 | 0.051 | |
| CRB2 | 12.27 ± 1.91 | 11.67 ± 2.17 | 10.59 ± 2.31 | 10.53 | 0.090 | |
| SdFRA | 8.46 ± 2.87 | 7.17 ± 2.12 | 5.24 ± 3.23 | 21.12 | 0.165 | |
| SdCRA | 9.67 ± 2.65 | 8.87 ± 2.31 | 6.95 ± 2.69 | 17.13 | 0.138 | |
| DR | 22.02 ± 3.64 | 21.00 ± 3.50 | 17.54 ± 5.36 | 19.37 | 0.153 |
HC, healthy controls; CP-MS, Multiple Sclerosis cognitively preserved; CI-MS, Multiple Sclerosis cognitively impaired.
Statistically significant p-values are shown in bold (p < 0.01).
ANOVA with post-hoc analysis showed statistically significant differences between
HC vs. CP-MS,
HC vs. CI-MS, and
CP-MS vs. CI-MS.
LASSI-L intrusions across diagnostic groups (total intrusions, intrusions from other list, and percentage of intrusion errors).
| ti-FRA1 | 0.10 ± 0.33 | 0.54 ± 0.85 | 0.32 ± 0.65 | 11.30 | 0.096 | |
| ti-CRA1 | 0.28 ± 0.64 | 0.71 ± 0.93 | 0.73 ± 1.00 | 7.70 | 0.067 | |
| ti-CRA2 | 0.10 ± 0.35 | 0.35 ± 0.59 | 0.44 ± 0.74 | 8.54 | 0.074 | |
| ti-FRB1 | 0.40 ± 0.84 | 0.75 ± 1.11 | 0.98 ± 0.12 | 6.20 | 0.055 | |
| i-FRB1 | 0.40 ± 0.78 | 0.85 ± 1.28 | 0.85 ± 0.98 | 5.88 | 0.052 | |
| ti-CRB1 | 1.10 ± 1.75 | 2.23 ± 2.33 | 2.29 ± 2.14 | 9.15 | 0.079 | |
| i-CRB1 | 1.01 ± 1.66 | 2.13 ± 2.24 | 2.17 ± 2.07 | 9.68 | 0.083 | |
| ti-CRB2 | 0.74 ± 1.26 | 1.63 ± 1.91 | 1.63 ± 1.44 | 9.73 | 0.083 | |
| i-CRB2 | 0.71 ± 1.12 | 1.48 ± 1.77 | 1.51 ± 1.36 | 8.97 | 0.077 | |
| ti-SdFRA | 0.61 ± 1.08 | 1.17 ± 1.45 | 1.71 ± 2.00 | 10.45 | 0.089 | |
| i-SdFRA | 0.56 ± 1.02 | 1.06 ± 1.37 | 1.54 ± 1.96 | 8.91 | 0.077 | |
| ti-SdCRA | 1.11 ± 1.44 | 1.96 ± 1.60 | 2.68 ± 2.57 | 13.80 | 0.114 | |
| i-SdCRA | 1.06 ± 1.42 | 1.67 ± 1.51 | 2.41 ± 2.28 | 11.13 | 0.094 | |
| PIE CRB1 | 0.10 ± 0.15 | 0.20 ± 0.18 | 0.23 ± 0.20 | 11.38 | 0.096 | |
| PIE CRB2 | 0.05 ± 0.08 | 0.10 ± 0.11 | 0.12 ± 0.11 | 10.86 | 0.092 | |
| PIE SdCRA | 0.10 ± 0.13 | 0.15 ± 0.14 | 0.25 ± 0.19 | 15.46 | 0.126 |
Statistically significant p-values are shown in bold (p < 0.01).
ANOVA with post-hoc analysis showed statistically significant differences between
HC vs. CP-MS,
HC vs. CI-MS, and
CP-MS vs. CI-MS.
ti-FRA1, total intrusions; i-FRA1, intrusions from other list; PIE, percentage of intrusions index.
Comparison between MS patients according to the recognition of formal disability.
| Age | 51.10 ± 6.45 | 44.12 ± 10.24 | 3.717 | |
| Years of evolution of disease | 18.80 ± 9.11 | 12.43 ± 8.15 | 3.014 | |
| Years of education | 17.45 ± 10.97 | 16.05 ± 3.07 | 0.968 | 0.336 |
| FRA1 | 7.75 ± 2.53 | 9.84 ± 2.19 | −3.645 | |
| CRA1 | 8.00 ± 2.02 | 10.21 ± 2.18 | −4.239 | |
| CRA2 | 11.20 ± 2.33 | 13.51 ± 1.42 | −4.216 | |
| FRB1 | 5.35 ± 2.23 | 7.49 ± 2.13 | −3.940 | |
| CRB1 | 5.80 ± 1.85 | 7.60 ± 2.54 | −2.952 | |
| CRB2 | 9.75 ± 2.33 | 11.59 ± 2.12 | −3.354 | |
| SdFRA | 3.85 ± 2.73 | 7.00 ± 2.45 | −4.958 | |
| SdCRA | 6.10 ± 2.57 | 8.55 ± 2.43 | −3.813 | |
| DR | 15.20 ± 4.56 | 20.64 ± 4.07 | −5.163 |
Statistically significant p-values are shown in bold (p < 0.01).